Efficacy of Benzoyl Peroxide (5.3%) Emollient Foam and Benzoyl Peroxide (8%) Wash in Reducing Propionibacterium acnes on the Back

June 2010 | Volume 9 | Issue 6 | Original Article | 622 | Copyright © June 2010


James J. Leyden MD

Department of Dermatology, University of Pennsylvania, Philadelphia, PA

the brief exposure in a “wash off “ product in an area with less density of sebaceous follicles and lipid than found on the face may not be sufficient for solubilization of BP particles in suspension in the wash formulation. Further studies with varying periods of time between application and rinsing would help clarify whether this hypothesis has merit. Likewise, it would be of interest to see how effective a “leave on” formulation is when used at home without supervision.

CONCLUSION

BP (5.3%) emollient foam effectively reduced P. acnes populations on the back and may offer a useful therapy for patients with acne on broad body surface areas. BP (8%) wash applied at home in the shower did not effectively reduce P. acnes populations on the back. Both treatments were well tolerated

Acknowledgements

The author thanks Brian Bulley MSc for editorial assistance.

Disclosures

The authors have no relevant conflicts of interest to disclose.
The manufacturer of the foam product sponsored this study.

REFERENCES

  1. Del Rosso JQ, Bikowski JB, Baum E, et al. A closer look at truncal acne vulgaris: Prevalence, severity and clinical significance. J Drugs Dermatol. 2007;6(6):597-600.
  2. Del Rosso JQ. Management of truncal acne vulgaris: Current perspectives on treatment. Cutis. 2006;77:285-289.
  3. Tan JKL, Tan J, Funbg K, et al. Prevalence and severity of facial and truncal acne in a referral cohort. J Drugs Dermatol. 2008;7(6):553- 556.
  4. Del Rosso JQ. Truncal acne vulgaris: The relative roles of topical and systemic antibiotic therapy. J Drugs Dermatol. 2007;6(2):148- 151.
  5. Del Rosso JQ. Pharmacotherapy update: Managing truncal acne vulgaris. Skin & Aging. 2005;(13)8:66-71.
  6. Del Rosso JQ. Management of superficial folliculitis with clindamycin 1% foam. Poster presented at American Academy of Dermatology, July 20-24, 2005; Chicago, IL.
  7. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: Focus on antibiotic resistance. Cutis. 2007;79(Suppl):9-25.
  8. Leyden JJ, Kaidbey K, Gans EH. The antimicrobial effect in vivo of minocycline, doxycycline and tetracycline in humans. J Dermatol Treat. 1996;7:223-225.
  9. Leyden JJ. The evolving role of Propionibacterium acnes in acne. Sem Cutan Med Surg. 2001;20:139-143.
  10. Eady EA, Bojar RA, Jones CE, et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol. 1996;134:107-113.
  11. Tschen E, Jones T. A new treatment for acne vulgaris combining benzoyl peroxide with clindamycin. J Drugs Dermatol. 2002;1:153- 157.
  12. Gans EH, Kligman AM. Comparative efficacy of clindamycin and benzoyl peroxide for in vivo suppression of Propionibacterium acnes. J Dermaolog Treat. 2002;13:107-110.
  13. Leyden JJ, Wortzman M, Baldwin, EK. Antibiotic-resistant Propionibacterium acnes suppressed by a benzoyl peroxide cleanser 6%. Cutis. 2008;82;417-421.
  14. Del Rosso JQ. Therapeutic cleansers: Keeping it clean. Skin & Aging. 2003;11:83-88.
  15. Weinberg JM. The utility of benzoyl peroxide in hyrdophase base (Brevoxyl®) in the treatment of acne vulgaris. J Drugs Dermatol. 2006;5(4);344-349.
  16. Williamson P, Kligman AM. A new method for the quantitative investigation of cutaneous bacteria. J Invest Dermatol. 1965;45:498- 503.
  17. Keyworth N, Millar MR, Holland KT. Swab-wash method for quantitation of cutaneous microflora. J Clin Microbio. 1990;28:941-943.

Address for Correspondence

James J. Leyden, MD505 ParkwayBroomall, PA 19008jjleyden@mindspring.com